BPG is committed to discovery and dissemination of knowledge
-
|
Homepage
|
-
|
Online Submission
|
- Number of total visits
-
31359991
- Number of visits today
- 10003
- Number of downloads
-
13925376
MEMBERSHIP
Cited by in F6Publishing
Number |
Citing Articles |
1 |
Gharebaghi N, Nejadrahim R, Mousavi SJ, Sadat-Ebrahimi SR, Hajizadeh R. The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial. BMC Infect Dis 2020;20:786. [PMID: 33087047 DOI: 10.1186/s12879-020-05507-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 18.5] [Reference Citation Analysis]
|
2 |
Kolahchi Z, Sohrabi H, Ekrami Nasab S, Jelodari Mamaghani H, Keyfari Alamdari M, Rezaei N. Potential therapeutic approach of intravenous immunoglobulin against COVID-19. Allergy Asthma Clin Immunol 2021;17:105. [PMID: 34627384 DOI: 10.1186/s13223-021-00609-3] [Reference Citation Analysis]
|
3 |
Peetermans M, Wan RYY, Camporota L, Barrett NA, Retter A. Use of Intravenous Immunoglobulins in Patients with Suspected Toxin-Mediated Shock Requiring Extracorporeal Membrane Oxygenation. Shock 2020;54:209-12. [PMID: 32044828 DOI: 10.1097/SHK.0000000000001519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345